Premium
Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study
Author(s) -
VazDaSilva Manuel,
Nunes Teresa,
Almeida Luis,
Gutierrez Maria J.,
Litwin Jeffrey S.,
SoaresDaSilva Patrício
Publication year - 2012
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270010391789
Subject(s) - qt interval , placebo , medicine , moxifloxacin , crossover study , anesthesia , confidence interval , repolarization , qrs complex , cardiology , electrophysiology , alternative medicine , pathology , microbiology and biotechnology , biology , antibiotics
This study investigated the effect of eslicarbazepine acetate (ESL) on cardiac repolarization in healthy adult volunteers. A randomized, placebo/active‐controlled, 4‐period crossover study was conducted in 67 participants. In 3 periods, participants received once‐daily doses of ESL 1200 mg, ESL 2400 mg, and placebo for 5 days; in 1 period, participants received placebo on days 1 to 4 and a 400‐mg moxifloxacin single dose on day 5. In each period, 24‐hour 12‐lead Holter monitoring was performed on days −;1 (baseline) and 5. There was no clinically relevant effect of ESL 1200 mg and 2400 mg versus placebo on cardiac depolarization or repolarization as measured by the QRS or QTc intervals, respectively. Mean PR interval increased following ESL 1200 mg and 2400 mg, but there was no participant with a PR interval above the upper limit of the normal range (200 ms). The upper bound of the 95% confidence interval for the placebo‐corrected change from baseline of the individually corrected QT interval (QTcI) following administration of ESL 1200 mg and ESL 2400 mg was <10 ms at every time point. Moxifloxacin caused an increase in QTcI above the 10‐ms threshold for clinical significance at several time points, demonstrating assay sensitivity. It is concluded that administration of ESL 1200 mg and ESL 2400 mg did not induce a clinically significant prolongation of the QTcI interval.